Tonix reports preliminary Q3 net loss $32M, plans Tonmya launch by Nov 2025

Tonix Pharmaceuticals Holding Corp.

Preliminary Q3 2025 net loss ~$32.0M vs $14.2M YoY; net revenue $3.3M vs $2.8M.
Cash and equivalents ~$190.1M at Sept 30, 2025; net operating cash use $28.8M.
Subsequent equity offerings net $29.3M; cash runway into Q1 2027.
U.S. commercial launch of Tonmya for fibromyalgia expected by end of Nov 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.